嵌合抗原受体 T 细胞 (CAR-T) 疗法彻底改变了复发/难治性非霍奇金淋巴瘤 (R/R NHL) 患者的治疗方法。然而，长期预后却令人沮丧。此外，有必要紧急解决两个关键问题：在CAR-T输注前最大限度地减少肿瘤负荷，并控制CAR-T治疗后的致命毒性。通过结合放疗（RT），可以提高CAR-T的安全性和有效性。 RT可以作为桥接治疗，减少CAR-T输注前的肿瘤负荷，从而实现安全、成功的CAR-T输注，并在CAR-T治疗失败时作为挽救治疗。本综述旨在讨论支持在 CAR-T 疗法中使用放疗治疗 R/R NHL 患者的当前证据。尽管大多数研究表明放疗在接受 CAR-T 治疗的患者的联合治疗中具有积极作用，但从中获得的协同作用仍不确定。此外，最佳剂量/分数和辐射反应需要进一步研究。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment approach for patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). However, the long-term prognosis has been discouraging. Moreover, the urgent resolution of two critical issues is necessary: minimize tumor burden before CAR-T infusion and control fatal toxicities post CAR-T therapy. By combining radiotherapy (RT), the safety and efficacy of CAR-T can be improved. RT can serve as bridging therapy, reducing the tumor burden before CAR-T infusion, thus enabling safe and successful CAR-T infusion, and as salvage therapy in cases of CAR-T therapy failure. This review aims to discuss the current evidence supporting the use of RT in CAR-T therapy for patients with R/R NHL. Although most studies have shown a positive role of RT in combined modality treatments for patients undergoing CAR-T therapy, the synergy gained from these remains uncertain. Furthermore, the optimal dose/fraction and radiation response require further investigation.Copyright © 2024 Elsevier B.V. All rights reserved.